News & Blog
News & Blog
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohor
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
April 2023 – Advocacy Newsletter
First Medication to Treat Friedreich’s Ataxia Approved on Rare Disease Day!
February 2023 – Advocacy Newsletter
A Gene-Edited Cell Therapy for an Incurable Disease: Researchers Receive USD 4.8M Grant to Treat Friedreich’s Ataxia
Dr. Stepanova Presented with $20,000 Research Grant from Uplifting Athletes
Prime Medicine announces recent progress and highlights 2023 strategic priorities
New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve ...